GLP1R and obesity due to melanocortin 4 receptor deficiency: Semaglutide, a glucagon‐like peptide‐1 (GLP‐1) receptor agonist, has shown promising effects in reducing cardiovascular events in patients with obesity and heart failure (HF) with preserved ejection fraction (HFpEF) irrespective of concomitant diabetes.